Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005
- PMID: 20447723
- PMCID: PMC2885489
- DOI: 10.1016/j.jaad.2009.07.027
Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005
Abstract
Background: Primary cutaneous adenoid cystic carcinoma (PCACC) is a rare appendageal tumor of uncertain origin. Details on epidemiologic features of PCACC are sparse and largely based on clinical reports.
Objective: We sought to develop an understanding of PCACC incidence, survival, and associated cancers using population-based data.
Methods: We used the Surveillance, Epidemiology, and End Results program to calculate age-adjusted incidence rates (IRs), IR ratios, 95% confidence intervals, standardized incidence ratios (SIRs), and 5-year relative survival of PCACC diagnosed during 1976 to 2005.
Results: In a population of 723,174,580 person-years, the overall PCACC IR was 0.23 per 1 million person-years (n = 152), with similar IRs among male and female patients (IR = 0.24). Most cases of PCACC presented at a localized stage and arose on the face/head/neck. Among 122 of the 2-month survivors of PCACC and more than 2.4 million 2-month cancer survivors, risk of associated cancers overall was not significantly increased (SIR = 1.17 [n = 24] and SIR = 1.43 [n = 16], respectively). However, PCACC was associated with significantly increased risks of subsequent lymphohematopoietic (n = 6; SIR = 3.70) and thyroid (n = 2; SIR = 15.25) cancers, whereas the converse associations were not observed. Five-year relative survival was excellent (96.1%; n = 122) with more favorable survival noted for PCACC involving the face/head/neck than the trunk.
Limitations: A pathologic review of reported cases was not undertaken.
Conclusion: PCACC is a rare appendageal tumor that affects male and female individuals equally, primarily presents at localized stage, predominates in the face/head/neck, and is associated with favorable survival. Immunosuppression does not appear to contribute to the development of PCACC, and the observed associated cancer patterns will need to be confirmed in larger studies.
Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Conflict of interest statement
Figures
References
-
- Requena L, Mengesha YM, Kutzner H, Kohler S, Hurt MA, Argenyi ZB, et al. Malignant tumours with apocrine and eccrine differentiation. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours. Lyon: IARC Press; 2006. pp. 125–38.
-
- Boggio R. Letter: Adenoid cystic carcinoma of scalp. Arch Dermatol. 1975;111:793–4. - PubMed
-
- Freeman RG, Winkelmann RK. Basal cell tumor with eccrine differentiation (eccrine epithelioma) Arch Dermatol. 1969;100:234–42. - PubMed
-
- Miller WL. Sweat-gland carcinoma. A clinicopathologic problem. Am J Clin Pathol. 1967;47:767–80. - PubMed
-
- Stout AP, Cooley SG. Carcinoma of sweat glands. Cancer. 1951;4:521–36. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources